Scleroderma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Scleroderma}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{Reflist|2...") |
m (Bot: Removing from Primary care) |
||
| (5 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Scleroderma}} | {{Scleroderma}} | ||
{{CMG}}; {{AE}} {{MKA}} | |||
==Overview== | |||
There are no established measures for the secondary prevention of scleroderma. However, effective measures for the secondary prevention of [[pulmonary arterial hypertension]] and scleroderma [[renal]] crisis in patients with scleroderma include [[Screening test|screening]]. | |||
==Secondary Prevention== | |||
*There are no established measures for the secondary prevention of scleroderma. However, effective measures for the secondary prevention of [[pulmonary arterial hypertension]] and scleroderma [[renal]] crisis in patients with scleroderma include:<ref name="pmid19389575">{{cite journal |vauthors=McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J |title=ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association |journal=J. Am. Coll. Cardiol. |volume=53 |issue=17 |pages=1573–619 |date=April 2009 |pmid=19389575 |doi=10.1016/j.jacc.2009.01.004 |url=}}</ref><ref name="pmid24022584">{{cite journal |vauthors=Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV |title=Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension |journal=Arthritis Rheum. |volume=65 |issue=12 |pages=3194–201 |date=December 2013 |pmid=24022584 |pmc=3883571 |doi=10.1002/art.38172 |url=}}</ref><ref name="pmid20534372">{{cite journal |vauthors=Khanna D, Denton CP |title=Evidence-based management of rapidly progressing systemic sclerosis |journal=Best Pract Res Clin Rheumatol |volume=24 |issue=3 |pages=387–400 |date=June 2010 |pmid=20534372 |pmc=2884006 |doi=10.1016/j.berh.2009.12.002 |url=}}</ref> | |||
**Annual screening with trans thoracic echocardiogram ([[TTE]]) and [[Pulmonary function tests|pulmonary function tests (PFTs)]] for [[pulmonary hypertension]]. | |||
**Regular [[blood pressure]] monitoring at home for early detection of scleroderma renal crisis. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | {{WH}} | ||
{{WS}} | |||
[[Category:Up-To-Date]] | |||
[[Category:Medicine]] | |||
[[Category:Dermatology]] | |||
[[Category:Rheumatology]] | |||
Latest revision as of 00:06, 30 July 2020
|
Scleroderma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Scleroderma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Scleroderma secondary prevention |
|
Risk calculators and risk factors for Scleroderma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
There are no established measures for the secondary prevention of scleroderma. However, effective measures for the secondary prevention of pulmonary arterial hypertension and scleroderma renal crisis in patients with scleroderma include screening.
Secondary Prevention
- There are no established measures for the secondary prevention of scleroderma. However, effective measures for the secondary prevention of pulmonary arterial hypertension and scleroderma renal crisis in patients with scleroderma include:[1][2][3]
- Annual screening with trans thoracic echocardiogram (TTE) and pulmonary function tests (PFTs) for pulmonary hypertension.
- Regular blood pressure monitoring at home for early detection of scleroderma renal crisis.
References
- ↑ McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J (April 2009). "ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association". J. Am. Coll. Cardiol. 53 (17): 1573–619. doi:10.1016/j.jacc.2009.01.004. PMID 19389575.
- ↑ Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV (December 2013). "Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension". Arthritis Rheum. 65 (12): 3194–201. doi:10.1002/art.38172. PMC 3883571. PMID 24022584.
- ↑ Khanna D, Denton CP (June 2010). "Evidence-based management of rapidly progressing systemic sclerosis". Best Pract Res Clin Rheumatol. 24 (3): 387–400. doi:10.1016/j.berh.2009.12.002. PMC 2884006. PMID 20534372.